The term nonalcoholic fatty liver disease (NAFLD) covers a pathologic spectrum from lipid
accumulation alone (simple steatosis) to steatosis with associated inflammation and fibrosis …

The prevalence and diagnosis of nonalcoholic fatty liver disease (NAFLD) is on the rise
worldwide and currently has no FDA-approved pharmacotherapy. The increase in disease …

Non-alcoholic fatty liver disease (NAFLD) is a clinicopathological change characterized by
the accumulation of triglycerides in hepatocytes and has frequently been associated with …

Non-alcoholic fatty liver disease (NAFLD) is associated with the growing incidence of
metabolic syndrome. Diet is an important contributor to the pathogenesis of NAFLD. In this …

Nonalcoholic fatty liver disease (NAFLD) is currently the most common form of chronic liver
disease affecting both adults and children in the United States and many other parts of the …

Introduction Non-alcoholic fatty liver disease (NAFLD) affects~ 25% of world population and
cases have increased in recent decades. These anomalies have several etiologies; …

Non-alcoholic fatty liver disease (NAFLD) is a prevalent metabolic condition closely
associated with genetic predisposition and/or obesity, lipodystrophy, and insulin resistance …

Non-alcoholic fatty liver disease (NAFLD) is now the most common liver disease in both
adults and children worldwide. As a disease spectrum, NAFLD may progress from simple …

Non-alcoholic fatty liver disease (NAFLD) is an emerging metabolic-related disorder
characterized by fatty infiltration of the liver in the absence of alcohol consumption. NAFLD …

Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of disorders ranging
from simple steatosis to non-alcoholic steatohepatitis (NASH). Hepatic steatosis may result …